OTC Markets OTCPK - Delayed Quote USD

Daiichi Sankyo Company, Limited (DSKYF)

Compare
25.50
0.00
(0.00%)
At close: January 10 at 3:00:00 PM EST
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,687,028,000.00
1,601,688,000.00
1,278,478,000.00
1,044,892,000.00
962,516,000.00
Cost of Revenue
416,696,000.00
415,322,000.00
363,525,000.00
353,400,000.00
338,289,000.00
Gross Profit
1,270,332,000.00
1,186,366,000.00
914,952,000.00
691,491,000.00
624,227,000.00
Operating Expense
1,009,797,000.00
974,777,000.00
794,370,000.00
618,464,000.00
560,432,000.00
Operating Income
260,535,000.00
211,589,000.00
120,582,000.00
73,027,000.00
63,795,000.00
Net Non Operating Interest Income Expense
34,526,000.00
25,461,000.00
6,293,000.00
361,000.00
10,161,000.00
Pretax Income
295,299,000.00
237,234,000.00
126,854,000.00
73,516,000.00
74,124,000.00
Tax Provision
65,911,000.00
36,217,000.00
17,666,000.00
6,543,000.00
-1,705,000.00
Net Income Common Stockholders
229,101,000.00
200,731,000.00
109,188,000.00
66,972,000.00
75,958,000.00
Diluted NI Available to Com Stockholders
229,101,000.00
200,731,000.00
109,188,000.00
66,972,000.00
75,958,000.00
Basic EPS
119.55
104.69
56.95
34.94
39.17
Diluted EPS
119.47
104.62
56.91
34.91
39.11
Basic Average Shares
1,916,694.30
1,917,384.66
1,917,034.61
1,916,602.00
1,939,343.00
Diluted Average Shares
1,917,928.41
1,918,667.56
1,918,587.00
1,918,499.00
1,941,975.00
Total Operating Income as Reported
260,535,000.00
211,588,000.00
120,580,000.00
73,025,000.00
63,795,000.00
Total Expenses
1,426,493,000.00
1,390,099,000.00
1,157,895,000.00
971,864,000.00
898,721,000.00
Net Income from Continuing & Discontinued Operation
229,101,000.00
200,731,000.00
109,188,000.00
66,972,000.00
75,958,000.00
Normalized Income
229,101,000.00
200,731,000.00
109,188,000.00
66,972,000.00
75,958,000.00
Interest Income
41,799,000.00
31,487,000.00
14,773,000.00
6,114,000.00
12,916,000.00
Interest Expense
7,273,000.00
6,026,000.00
8,480,000.00
5,753,000.00
2,755,000.00
Net Interest Income
34,526,000.00
25,461,000.00
6,293,000.00
361,000.00
10,161,000.00
EBIT
302,572,000.00
243,260,000.00
135,334,000.00
79,269,000.00
76,879,000.00
EBITDA
364,664,000.00
302,906,000.00
203,123,000.00
137,514,000.00
134,261,000.00
Reconciled Cost of Revenue
416,696,000.00
415,322,000.00
363,525,000.00
353,400,000.00
338,289,000.00
Reconciled Depreciation
62,092,000.00
59,646,000.00
67,789,000.00
58,245,000.00
57,382,000.00
Net Income from Continuing Operation Net Minority Interest
229,101,000.00
200,731,000.00
109,188,000.00
66,972,000.00
75,958,000.00
Normalized EBITDA
364,664,000.00
302,906,000.00
203,123,000.00
137,514,000.00
134,261,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
3/31/2021 - 6/24/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CHGCY Chugai Pharmaceutical Co., Ltd.
21.10
-0.28%
 
ALPMF Astellas Pharma Inc.
9.60
+0.52%
 
BAYZF Bayer Aktiengesellschaft
20.73
0.00%
 
AZNCF AstraZeneca PLC
135.50
0.00%
 
RHHBF Roche Holding AG
301.37
0.00%
 
LLY.F Eli Lilly and Company
774.00
+1.08%
 
NONOF Novo Nordisk A/S
85.80
0.00%
 
RHHBY Roche Holding AG
36.46
-0.27%
 
BAYRY Bayer Aktiengesellschaft
5.12
+0.99%
 
SAN.PA Sanofi
95.61
-0.72%